title: [The clinical efficacy of Bladder Chek NMP22 in urothelial cancer].
abstract: The purpose of this study is to investigate the clinical efficacy of a quick test for NMP22 (Nuclear Matrix Protein 22), Bladder Chek NMP22, as a screening test for urothelial cancers. The subjects include 51 cases(43 cases with pathologically confirmed bladder cancer, and 8 cases with upper urothelial cancer). Bladder Chek NMP22 revealed false positive in the urine with more than 1 x 10(5)/microliter of erythrocytes and 1 x 10(3)/microliter of white blood cells. Thus, showing that Bladder Chek NMP22 was not relatively affected by the contaminated erythrocytes and white blood cells, compared with other conventional methods to detect urinary malignant disease. In 51 cases diagnosed of having pathologically urothelial cancers, the sensitivity of Bladder Chek NMP22 was 56.8%. Bladder Chek NMP22 demonstrated more excellent sensitivity than the other methods. The positivity of Grade3 patients was 68.4%, 68.4% and 63.2% by Bladder Chek NMP22, NMP22 ELISA and urinary cytology. In contrast, the positivity rate for the patients with Grade1 stage was 58.3%, 33.3% and 8.3%. There is no significance of positivity rate between each examination in patients with high grade cancer. However Bladder Chek NMP22 demonstrated the higher positivity in patients with low grade cancer. Bladder Chek NMP22 test could be an easy and confidential method to detect urothelial cancers, especially with low grade, as a screening examination.
authors.affiliation: Department of Clinical Laboratory Medicine of Kidney Center, Tokyo Women's Medical University, Sinjuku-ku, Tokyo 162-8666.
authors.forename: Takashi
authors.initials: T
authors.lastname: Yokoyama
authors.forename: Rumi
authors.initials: R
authors.lastname: Sekigawa
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Hayashi
authors.forename: Shigeru
authors.initials: S
authors.lastname: Horita
authors.forename: Toshiko
authors.initials: T
authors.lastname: Kanamuro
authors.forename: Yuji
authors.initials: Y
authors.lastname: Nonami
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Sawada
authors.forename: Toshirou
authors.initials: T
authors.lastname: Nishikawa
authors.forename: Makio
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: Hideki
authors.initials: H
authors.lastname: Ishida
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Goya
authors.forename: Hayakazu
authors.initials: H
authors.lastname: Nakazawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Toma
mesh_terms: D014408:Biomarkers, Tumor / Q000652:urine*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005189:False Positive Reactions; D006801:Humans; D008403:Mass Screening / Q000379:methods; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000652:urine*; D012680:Sensitivity and Specificity; D014516:Ureteral Neoplasms / Q000175:diagnosis* / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; C100379:nuclear matrix protein 22